Evidence map›Paper›PMID 36225939›Full record

ArticleFrontiers in immunology2022

Integration of single-cell RNA sequencing and bulk RNA sequencing to reveal an immunogenic cell death-related 5-gene panel as a prognostic model for osteosarcoma.

Jiaqi Yang, Jian Zhang, Song Na, Zhizhou Wang, Hanshuo Li, Yuxin Su, Li Ji, Xin Tang, Jun Yang, Lu Xu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jiaqi YangDepartment of Dermatology, Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Jian ZhangDepartment of Orthopedics, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Song NaEmergency Intensive Care Unit, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
Zhizhou WangDepartment of General Surgery, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Hanshuo LiDepartment of General Surgery, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Yuxin SuCardiovascular Research Institute of Northern Theater Command General Hospital, Shenyang, China.
Li JiDepartment of Gastroenterology, DongZhiMen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Xin TangDepartment of Orthopedics, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Jun YangDepartment of Orthopedics, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Lu XuDepartment of Dermatology, Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Dalian Medical University · CNDongzhimen Hospital Affiliated to Beijing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite the comparatively low prevalence of osteosarcoma (OS) compared to other cancer types, metastatic OS has a poor overall survival rate of fewer than 30%. Accumulating data has shown the crucial functions of immunogenic cell death (ICD) in various cancers; nevertheless, the relationship between ICD and OS was not previously well understood. This research aims to determine the function of ICD in OS and construct an ICD-based prognostic panel. Methods: Single cell RNA sequencing data from GSE162454 dataset distinguished malignant cells from normal cells in OS. The discrepancy in ICD scores and corresponding gene expression was intensively explored between malignant cells and normal cells. Using the RNA sequencing data of the TARGET-OS, GSE16091, GSE21257, and GSE39058 datasets, the molecular subtype of OS was determined by clustering seventeen ICD-related genes obtained from the literature. Differentially expressed genes (DEGs) between different molecular subtypes were identified to develop a novel ICD-associated prognostic panel. Results: The malignant cells had a remarkable decrease in the ICD scores and corresponding gene expression compared with normal cells. A total of 212 OS patients were successfully stratified into two subtypes: C1 and C2. C1-like OS patients were characterized by better prognostic outcomes, overexpression of ICD genes, activation of the ICD pathway, high inflitration abundance of immunocytes, and low expression levels of immune checkpoint genes (ICGs); however, the reverse is true in C2-like OS patients. Utilizing the limma programme in R, the DEGs between two subtypes were determined, and a 5-gene risk panel consisting of BAMBI, TMCC2, NOX4, DKK1, and CBS was developed through LASSO-Cox regression analysis. The internal- and external-verification cohorts were employed to verify the efficacy and precision of the risk panel. The AUC values of ROC curves indicated excellent prognostic prediction values of our risk panel. Conclusions: Overall, ICD represented a protective factor against OS, and our 5-gene risk panel serving as a biomarker could effectively evaluate the prognostic risk in patients with OS.

Indexed as

Bone NeoplasmsOsteosarcomaGene Expression Regulation, NeoplasticHumansImmunogenic Cell DeathPrognosisSequence Analysis, RNAbulk RNA sequencingimmunogenic cell deathmolecular subtypeosteosarcomaprognostic panelsingle cell RNA sequencing

Identifiers

PMID36225939
PMCPMC9549151
OpenAlexW4297227042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.